Last Updated: May 31, 2026

SEVELAMER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Sevelamer patents expire, and what generic alternatives are available?

Sevelamer is a drug marketed by Aurobindo Pharma, Bionpharma, Chartwell Rx, Dr Reddys, Impax, Invagen Pharms, Lupin Ltd, Macleods Pharms Ltd, Strides Pharma Intl, Torrent, Amneal Pharms Co, Arthur Grp, Epic Pharma Llc, Impax Labs Inc, Micro Labs, Navinta Llc, Rising, Shandong Xinhua, Strides Pharma, Zydus Pharms, Aurobindo Pharma Ltd, and Glenmark Pharms Ltd. and is included in thirty-two NDAs.

The generic ingredient in SEVELAMER is sevelamer hydrochloride. There are thirty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the sevelamer hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sevelamer

A generic version of SEVELAMER was approved as sevelamer hydrochloride by GLENMARK PHARMS LTD on February 8th, 2019.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for SEVELAMER?
  • What are the global sales for SEVELAMER?
  • What is Average Wholesale Price for SEVELAMER?
Summary for SEVELAMER
US Patents:0
Applicants:22
NDAs:32
Drug Prices: Drug price information for SEVELAMER
DailyMed Link:SEVELAMER at DailyMed
Drug patent expirations by year for SEVELAMER
Drug Prices for SEVELAMER

See drug prices for SEVELAMER

Drug Sales Revenue Trends for SEVELAMER

See drug sales revenues for SEVELAMER

US Patents and Regulatory Information for SEVELAMER

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd SEVELAMER HYDROCHLORIDE sevelamer hydrochloride TABLET;ORAL 213145-002 Jun 16, 2021 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Shandong Xinhua SEVELAMER CARBONATE sevelamer carbonate TABLET;ORAL 215998-001 Oct 24, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Rising SEVELAMER HYDROCHLORIDE sevelamer hydrochloride TABLET;ORAL 201068-001 Dec 14, 2020 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Macleods Pharms Ltd SEVELAMER CARBONATE sevelamer carbonate TABLET;ORAL 206100-001 Apr 19, 2023 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Strides Pharma SEVELAMER CARBONATE sevelamer carbonate TABLET;ORAL 211915-001 May 9, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Micro Labs SEVELAMER CARBONATE sevelamer carbonate TABLET;ORAL 215537-001 Feb 7, 2022 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma SEVELAMER CARBONATE sevelamer carbonate FOR SUSPENSION;ORAL 207624-001 Jun 13, 2017 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links